June 22, 2020 / 1:24 PM / 13 days ago

BRIEF-Tyme Presents New Preclinical Data Supporting SM-88 Mechanism Of Action At AACR 2020

June 22 (Reuters) - Tyme Technologies Inc:

* TYME PRESENTS NEW PRECLINICAL DATA SUPPORTING SM-88 MECHANISM OF ACTION AT AACR 2020

* TYME TECHNOLOGIES- PRECLINICAL DATA SHOWED STATISTICALLY SIGNIFICANT TUMOR REDUCTION IN SM-88 TREATED ARMS VERSUS CONTROLS

* TYME TECHNOLOGIES- PRECLINICAL RESULTS WERE SHOWED ACROSS MULTIPLE TUMOR TYPES INCLUDING, PANCREATIC, COLON, BREAST, AND OVARIAN

* TYME TECHNOLOGIES - REDUCTION OF IMMUNOSUPPRESSIVE CELLS IN TUMOR MICROENVIRONMENT SUPPORTS EXPLORING COMBINATION WITH IMMUNO-ONCOLOGY TREATMENTS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below